Rules
Aboutfair balancerisk disclosureindication on labelsubstantiationcomparativemisleading presentationname ingredientsubmissionpre approvalscientific exchangedisclosure
Naturepromotional
Document typeadvertisement
Risk info placementdistinct-part
Communication typeadvertisement
Regulatory classprescription-drug
Drug classprescription
Rx statusprescription
Advertising typeprescription-drug-advertisement
Populationhuman-use
Content triggerliterature-or-study-effectiveness-claim
Materialadvertisement
Content typeadvertisement
Active ingredient counttwo-or-more
Proprietary name basismixture-designation
Established name statusnone-for-mixture-designation
Drug classificationprescription
Labeling scenariosingle-proprietary-name-multiple-preparations-no-established-name
Prescription statusprescription-drug
Ad formattelevision
Intended specieshuman
Exemption statusnon-exempt
Approval pathwayaccelerated
7 of 251 rules — including rules the source does not limit to any one scope
US-NAME-020·Section II.ADisputed
Trademark and controlled-substance symbols do not count as intervening matter
notecheckable
US-NAME-026·Section II.BDisputed
Type size is measured by actual letter height, not point size
notecheckable
US-SCI-001·21 CFR 312.7(a)Disputed
Full Scientific Exchange About an Investigational Drug Is Not Restricted
noteneeds human judgment
US-ADM-012·Q.8/A.8, concluding paragraphAI-verified
Qualified personnel should review CFL promotional communications before dissemination
notecheckable
US-SUB-009·Section V, Recommendation 3AI-verified
Rely on published peer-reviewed or independent-source data to the greatest extent possible
noteneeds human judgment
US-SUB-010·Section V, Recommendation 3AI-verified
Use reprints only from journals with a stated conflict-of-interest disclosure policy
noteneeds human judgment
US-SUB-011·Section V, Recommendation 6Disputed
Provide a complete reference list for all information disseminated in the response
noteneeds human judgment